AB Science (AB.PA): Launch of a Phase 3 Clinical Trial in Alzheimer's Disease
5/20/2013 11:28:38 AM
More...
|
AB Science (AB.PA): 2012 Annual Financial Results and 2013 First Quarter Revenue
4/29/2013 12:03:47 PM
More...
|
AB Science (AB.PA) Reports Phase 3 Study Results of Masitinib in Combination With Gemzar® for Treatment of Pancreatic Cancer
10/31/2012 8:36:40 AM
More...
|
AB Science (AB.PA) Confirms the Filing for the Marketing Authorization Application to the European Medicines Agency of Masitinib in the Treatment of Pancreatic Cancer
10/16/2012 10:22:58 AM
More...
|
AB Science (AB.PA) Release: European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec® Resistant Gastro-Intestinal Stromal Tumor
10/4/2012 10:15:42 AM
More...
|
AB Science (AB.PA) Release: Masitinib Treatment of Progressive Multiple Sclerosis Publication in BMC Neurology
6/13/2012 10:36:23 AM
More...
|
AB Science (AB.PA) Announces Publication of Three American Society of Clinical Oncology Presentations Detailing the Results of Masitinib in the Treatment of Advanced GIST
6/5/2012 10:52:43 AM
More...
|
AB Science (AB.PA) Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as Compared to Pfizer Inc. (PFE)'s Sutent®in Gleevec®-resistant GIST
2/1/2012 10:55:07 AM
More...
|
AB Science (AB.PA) Announces Recruitment of First Patient in Phase 3 Study of Masitinib in Multiple Myeloma
10/17/2011 10:40:36 AM
More...
|
AB Science (AB.PA) Announces That FDA Authorization (IND) Has Been Granted for the Initiation of Its Phase 3 Study in Severe Asthma. Patient Recruitment Commences in the US
9/14/2011 10:15:00 AM
More...
|
|